These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37783120)

  • 1. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer.
    Jing M; He X; Cai CZ; Ma QZ; Li K; Zhang BX; Yin Y; Shi MS; Wang YS
    Biochem Biophys Res Commun; 2023 Nov; 681():218-224. PubMed ID: 37783120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
    Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
    Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
    Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
    Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy.
    Lu Y; Li Z; Zhu H; Zhao J; Xu M; Gu W
    Ann Palliat Med; 2021 Dec; 10(12):12886-12893. PubMed ID: 35016432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
    Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
    Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
    Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K; Fukuda K; Takahashi H; Tanimoto A; Nishiyama A; Arai S; Takeuchi S; Yamashita K; Ohtsubo K; Otani S; Yanagimura N; Suzuki C; Ikeda H; Tamura M; Matsumoto I; Yano S
    Cancer Sci; 2019 Oct; 110(10):3215-3224. PubMed ID: 31432603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
    Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current knowledge of small cell lung cancer transformation from non-small cell lung cancer.
    Giaccone G; He Y
    Semin Cancer Biol; 2023 Sep; 94():1-10. PubMed ID: 37244438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
    Zeng J; Ding X; Ding J; Wang X
    Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of non-small cell lung cancer into small cell lung cancer in a patient with advanced lung cancer: a case report.
    Yang Z; Lin Y; Wang H
    J Int Med Res; 2021 Aug; 49(8):3000605211035005. PubMed ID: 34396834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation from EGFR/PTEN co-mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis.
    Hayashi T; Takamochi K; Kohsaka S; Kishikawa S; Suehara Y; Takahashi F; Suzuki K; Saito T; Yao T
    Pathol Int; 2020 May; 70(5):295-299. PubMed ID: 32162763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.
    Chu X; Xu Y; Li Y; Zhou Y; Chu L; Yang X; Ni J; Li Y; Guo T; Zheng Z; Zheng Q; Yao Q; Li Y; Zhou X; Zhu Z
    Lung Cancer; 2022 Jul; 169():22-30. PubMed ID: 35609408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
    Wang X; Liang J; Li L; Pan Z; Wang L
    Anticancer Drugs; 2023 Feb; 34(2):306-310. PubMed ID: 36206142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.